Research programme: cellular immunotherapeutics - Commence Bio

Drug Profile

Research programme: cellular immunotherapeutics - Commence Bio

Alternative Names: CMB-100; CMB-200; MSC1-Commence Bio; MSC2-Commence Bio; STaRT™

Latest Information Update: 22 Jun 2016

Price : $50

At a glance

  • Originator Commence Bio
  • Class Immunotherapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders; Ovarian cancer

Most Recent Events

  • 20 Jun 2016 Commence Bio has patent protection for STaRT 41™ technology in USA
  • 01 Nov 2015 Preclinical trials in Ovarian cancer in USA (IV) before November 2015
  • 01 Nov 2015 Preclinical trials in Autoimmune disorders in USA (IV) before November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top